KRAS Allelic Imbalance: Strengths and Weaknesses in Numbers.
29 Mar 2018The identification of therapeutic vulnerabilities in mutant KRAS tumors has proven difficult to achieve. Burgess and colleagues recently reported in Cell that mutant/wild-type Kras allelic dosage determines clonal fitness and MEK inhibitor sensitivity in a leukemia model, demonstrating that KRAS allelic imbalance is likely an important and overlooked variable.
| Authors: | Doherty, Gary, Kerr, Emma M, Pedro Martins, Carla |
| Institution: | University of Cambridge |
| Keywords: | Humans, Leukemia, Benzamides, Diphenylamine, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Gene Dosage, Allelic Imbalance, Models, Theoretical, Proto-Oncogene Proteins p21(ras) |